Trial intelligence / Profile preview

Neoadjuvant docetaxel + cisplatin + capecitabine with protocolized surgery in resectable gastric cancer

2007-007273-23Phase 2Active

Sponsor
Jeroen Bosch Hospital
Start
Dec 2007
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of docetaxel, cisplatin and capecitabine in gastric adenocarcinoma, sponsored by Jeroen Bosch Hospital. Primary endpoints: Radiologic response rate, Operability rate and 4 more. Started Dec 2007; status: active.

02

Drugs

docetaxelcisplatincapecitabine
03

Conditions

gastric adenocarcinoma

Beyond the preview

Go deeper on 2007-007273-23.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-007273-23.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call